Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 05, 2015 1:15 PM ET

Capital Markets

Company Overview of MPM Capital

Company Overview

MPM Capital is a private equity and venture capital firm specializing in seed, startup, early ventures, emerging growth, middle market, mature, mid venture, late venture, buyout, recapitalization, PIPES, and growth equity investments. The firm makes its venture investments through its MPM BioVentures fund and invests in the public markets through MPM BioEquities hedge fund. It invests in growth stage in in the biotechnology, healthcare, and life sciences sector. It invests in the seed stage through early clinical development stage of a company and invests in late stage in biopharmaceutical and diagnostics companies with clinical proof-of-concept data. It prefers to invest in medical technolo...

450 Kendall Street

Cambridge, MA 02142

United States

Founded in 1996





Key Executives for MPM Capital

Co-Founder, Managing Director and Managing Partner
Age: 52
Managing Director
Age: 57
Chief Financial Officer
Chief Operating Officer and General Counsel
Managing Director
Age: 43
Compensation as of Fiscal Year 2015.

MPM Capital Key Developments

MPM Capital Appoints Briggs W. Morrison, M.D. as Managing Director

MPM Capital announced the appointment of Briggs W. Morrison, M.D., to the position of Managing Director. Dr. Morrison was recently appointed Chief Executive Officer of Syndax Pharmaceuticals Inc., after serving as Chief Medical Officer and Executive Vice President for R&D at AstraZeneca.

MPM Capital Appoints Pablo J. Cagnoni, M.D. as Managing Director

MPM Capital announced the appointment of former President of Onyx Pharmaceuticals Pablo J. Cagnoni, M.D. as Managing Director (MD). In addition to serving as an MPM MD, Dr. Cagnoni is a co-founder of Vesuvius, an MPM-founded cancer immunotherapy company, and has taken on the role of President and Chief Executive Officer. Over of the course of his career as an oncologist and pharmaceutical executive, Dr. Cagnoni has been committed to advancing the development of breakthrough treatments for patients with cancer and other debilitating diseases. He has played a key role in the development, approval and/or commercialization of several life-changing medicines, including Afinitor®, Blinctyo®, Exjade®, Folotyn®, Glivec®, Jakavi®, Kyprolis®, Signifor®, Tarceva® and Tasigna®, among them.

MPM Capital Presents at Boston CEO Conference, May-27-2015 10:50 AM

MPM Capital Presents at Boston CEO Conference, May-27-2015 10:50 AM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Ansbert K. Gadicke, Co-Founder, Managing Director, and General Partner.

Similar Private Companies By Industry

Company Name Region
TRADERight Corp United States
Capital Fiduciary Advisors, LLC United States
SEP Strategic Advisors United States
OTC Global Holdings, LP United States
White Grotto Acquisition Corp. United States

Recent Private Companies Transactions

Private Placement
August 3, 2015
Rhythm Metabolic, Inc.
Private Placement
May 1, 2015
Amphivena Therapeutics Inc.
Private Placement
May 1, 2015
Vesuvius Pharmaceuticals, Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MPM Capital, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at